(Hetero)aryl-Substituted Piperidinyl Derivatives for Selective USP7 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current USP7 inhibitors lack selectivity and have not progressed to clinical use, necessitating the development of new compounds that can effectively inhibit USP7 activity to address its overexpression in various cancers and related diseases.
Innovation Solution
Development of novel (hetero)aryl-substituted piperidinyl derivatives with specific structural features that inhibit USP7 activity, exhibiting pro-apoptotic and anti-proliferative properties, potentially usable in treating cancers and immune-related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing USP7 inhibitors are used, then USP7 activity can be inhibited, but selectivity is insufficient leading to off-target effects
Solution Approach 1:
The patent introduces specific local structural features at defined positions of the piperidinyl core - particularly the (hetero)aryl substitution pattern, the carbonyl group at position 3, and the hydroxyl group at position 4 - to create localized interaction zones that enhance selective binding to USP7 while minimizing off-target effects
Solution Approach 2:
The patent systematically varies key molecular parameters including the type of (hetero)aryl group, the length and substitution pattern of linker chains, and the stereochemistry of chiral centers to optimize both selectivity and potency, resulting in compounds with improved therapeutic profiles
2Reliability
If USP7 inhibition is achieved to treat cancer, then therapeutic effect is obtained, but current compounds have not progressed to clinical use due to lack of selectivity
Solution Approach 1:
The patent divides the molecule into distinct functional segments: a core piperidinyl structure, a (hetero)aryl substituent, a carbonyl-containing linker, and a hydroxyl group, where each segment contributes specifically to USP7 binding, allowing for systematic optimization of therapeutic properties while managing molecular complexity
Solution Approach 2:
The patent creates composite molecular structures combining heteroaryl rings with piperidinyl cores through defined linkers, producing compounds that exhibit synergistic properties for selective USP7 inhibition that neither component achieves alone
Data Source
AI summary
Compounds of formula (I):wherein R1, R2, J, K, L, n and W are as defined in the description.Medicinal products containing the same which are useful in treating conditions requiring pro-apoptotic and/or anti-proliferative agents.